Elsevier

Life Sciences

Volume 260, 1 November 2020, 118400
Life Sciences

Parameters predicting COVID-19-induced myocardial injury and mortality

https://doi.org/10.1016/j.lfs.2020.118400Get rights and content

Abstract

Clinical manifestations of COVID-19 affect many organs, including the heart. Cardiovascular disease is a dominant comorbidity and prognostic factors predicting risk for critical courses are highly needed. Moreover, immunomechanisms underlying COVID-induced myocardial damage are poorly understood.

Objective

To elucidate prognostic markers to identify patients at risk.

Results

Only patients with pericardial effusion (PE) developed a severe disease course, and those who died could be identified by a high CD8/Treg/monocyte ratio. Ten out of 19 COVID-19 patients presented with PE, 7 (78%) of these had elevated APACHE-II mortality risk-score, requiring mechanical ventilation. At admission, PE patients showed signs of systemic and cardiac inflammation in NMR and impaired cardiac function as detected by transthoracic echocardiography (TTE), whereas parameters of myocardial injury e.g. high sensitive troponin-t (hs-TnT) were not yet increased. During the course of disease, hs-TnT rose in 8 of the PE-patients above 16 ng/l, 7 had to undergo ventilatory therapy and 4 of them died. FACS at admission showed in PE patients elevated frequencies of CD3+CD8+ T cells among all CD3+ T-cells, and lower frequencies of Tregs and CD14+HLADR+-monocytes. A high CD8/Treg/monocyte ratio predicted a severe disease course in PE patients, and was associated with high serum levels of antiviral cytokines. By contrast, patients without PE and PE patients with a low CD8/Treg/monocyte ratio neither had to be intubated, nor died.

Conclusions

PE predicts cardiac injury in COVID-19 patients. Therefore, TTE should be performed at admission. Immunological parameters for dysfunctional antiviral immunity, such as the CD8/Treg/monocyte ratio used here, supports risk assessment by predicting poor prognosis.

Keywords

COVID-19
SARS-CoV-2
Pericardial effusion
CD8
Treg
Monocyte

Cited by (0)

Supported by grants from the German Heart Foundation F/27/20 and F/28/29 (to Drs. Dürr, Heine, Luetkens and Velten), from the Deutsche Forschungsgemeinschaft (DFG EXC2151 – 390873048 to Drs. Heine and Kurts, DFG CRCTR259 to Drs. Zimmer, Nickenig and Kurts, and a DFG Gottfried-Wilhelm Leibniz Price to Dr. Kurts).

1

Contributed equally.

View Abstract